PetMeds® to Ring Nasdaq Opening Bell in Celebration of National Pet Day on April 11th DELRAY BEACH, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- In celebration of National Pet Day, PetMed Express, Inc. (NASDAQ: PETS)—the original consumer pet healthcare company serving dogs, cats, and horses for nearly 30 years—will ring the Nasdaq Opening Bell this Friday, April 11, 2025. This momentous occasion honors the powerful bond between people and their pets and will feature adoptable rescue dogs from Bidawee, one of the nation’s oldest no-kill animal welfare organizations. It’s a tribute to the j...
PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY BEACH, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- , parent company of PetMeds and PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of Peter Batushansky to the Company’s Board of Directors (“the Board”), effective April 09, 2025. M...
The Tile Shop Expands Collaboration With HGTV’s Alison Victoria, Bringing “City Chic” Style Off the Screen and Into Homes Everywhere The latest styles from The Tile Shop and HGTV star are available now, only at tileshop.com and Tile Shop showrooms. MINNEAPOLIS, April 02, 2025 (GLOBE NEWSWIRE) -- Interior designer and HGTV star Alison Victoria has transformed countless spaces with her visionary eye and signature “city chic” style. Now, fans have even more ways to bring Victoria's designs off their screens and into their homes with the latest additions to the exclusive collection. Ini...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to three (3) newly hired employe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.